9. Use of a subpopulation T-cells with a $CD25^{+}CD6^{low/-}$ expression pattern in the manufacture of a medicament for treating an immune-based disorder in an individual, wherein the subpopulation of T-cells with a $CD25^{+}CD6^{low/-}$ expression pattern is obtained by:

obtaining a biological sample, the biological sample comprising a population of individual-compatible T-cells;

screening a sample comprising a population of T-cells to detect a level of cellular expression of at least two different biomarkers, the at least two different biomarkers including a CD25 biomarker and a CD6 biomarker; and

isolating a subpopulation of T-cells comprising a $CD25^{+}CD6^{low/-}$ expression pattern;

wherein the subpopulation T-cells with a $CD25^{+}CD6^{low/-}$ expression pattern is to be administered into the individual, thereby treating the immune reaction in the individual, and wherein the immune-based disorder is selected from a group consisting of an autoimmune condition, autoimmune disorder, autoimmune disease, a transplant rejection, a graft vs. host disease, a cancer, immune-based inflammatory diseases, allergies, asthma, persistent and progressive immune reactions to infectious non self-antigens that persist within mammals and humans and combinations of the immune-based disorders, and wherein the antigen is selected from a group consisting of bacterial, viral, fungal, or parasitic organisms.

10. The use of Claim 9, wherein the subpopulation T-cells with a $CD25^{+}CD6^{low/-}$ expression pattern is expanded prior to introducing the subpopulation T-cells with a $CD25^{+}$ $CD6^{low/-}$ expression pattern into the individual.

11. The use of Claim 9, wherein the screening step further includes

screening the sample comprising a population of T-cells to detect a level of cellular expression of a CD4 biomarker and isolating a subpopulation of T-cells comprising a $CD4^{+}CD25^{+}CD6^{low/-}$ expression pattern;

screening the sample comprising a population of T-cells to detect a level of cellular expression of a CD127 biomarker and isolating a subpopulation of T-cells comprising a $CD25^{+}CD6^{low/-}$ $CD127^{low/-}$ expression pattern; or

screening the sample comprising a population of T-cells to detect a level of cellular expression of a CD4 biomarker and a CD127 biomarker and isolating a subpopulation of T-cells comprising a $CD4^{+}$ $CD25^{+}CD6^{low/-}CD127^{low/-}$ expression pattern.

12. The use of Claim 9, wherein the immune-based disorder is an autoimmune condition, disorder or disease, a transplant rejection, a graft vs. host disease, or a persistent and progressive immune reaction to an infectious non-self antigen from bacterial, viral, fungal, or parasitic organisms.

13. A kit for identifying, isolating, and/or enriching a population of immunosuppressive regulatory T-cells, the kit comprising at least two different biomarker ligands, the at least two different biomarkers including a CD25 biomarker ligand and a CD6 biomarker ligand.

14. The kit of Claim 13, wherein the kit further includes a CD4 biomarker ligand, a CD127 biomarker ligand, a CD49d biomarker ligand, a CD45RA biomarker ligand, a HLA-DR biomarker ligand, a FoxP3

one of the four distinct maturation subsets of immunosuppressive regulatory T-cell populations is an immature or memory immunosuppressive regulatory T-cell population subset, the immature or memory immunosuppressive regulatory T-cell population subset comprising a $CD4^{+}CD25^{+}CD127^{low/-}CD45RA^{+}CCR4^{low}$ expression pattern, a $CD4^{+}CD25^{+}CD127^{low/-}CD45RA^{+}CD39^{low}$ expression pattern, or a $CD4^{+}CD25^{+}CD127^{low/-}CD45RA^{+}HLA\text{-}Dr^{low}$ expression pattern;

one of the four distinct maturation subsets of immunosuppressive regulatory T-cell populations is a mature or effector immunosuppressive regulatory T-cell population subset, the mature or effector immunosuppressive regulatory T-cell population subset comprising a $CD4^{+}CD25^{hi/+}CD127^{low/-}CCR4^{hi/+}$ expression pattern, a $CD4^{+}CD25^{hi/+}CD127^{low/-}CD45RA^{-}$ expression pattern, a $CD4^{+}CD25^{hi/+}CD127^{low/-}CD39^{hi/+}$ expression pattern, a $CD4^{+}CD25^{hi/+}CD127^{low/-}$ $CCR4^{hi/+}CD45RA^{-}$ expression pattern, or a $CD4^{+}CD25^{hi/+}CD127^{low/-}CCR4^{hi/+}CD39^{hi/+}$ expression pattern, or a $CD4^{+}CD25^{hi/+}CD127^{low/-}CCR4^{hi/+}HLA\text{-}DR^{low}$ expression pattern; and/or

one of the four distinct maturation subsets of immunosuppressive regulatory T-cell populations is a terminal differentiated immunosuppressive regulatory T-cell population subset, the terminal differentiated immunosuppressive regulatory T-cell population subset comprising a $CD4^{+}CD25^{hi/+}CD127^{hi/+}CCR4^{hi/+}$ expression pattern, a $CD4^{+}CD25^{hi/+}CD127^{hi/+}CD45RA^{-}$ expression pattern, a $CD4^{+}CD25^{hi/+}CD127^{hi/+}CD39^{low}$ expression pattern, a $CD4^{+}CD25^{hi/+}CD127^{hi/+}HLA\text{-}Dr^{low}$ expression pattern, a $CD4^{+}CD25^{hi/+}CD127^{hi/+}CCR4^{hi/+}CD45RA^{-}$ expression pattern, a $CD4^{+}CD25^{hi/+}$ $CD127^{hi/+}CCR4^{hi/+}CD39^{low}$ expression pattern, or a $CD4^{+}CD25^{hi/+}CD127^{hi/+}CCR4^{hi/+}HLA\text{-}DR^{low}$ expression pattern.

25. The method of Claim 23, wherein the method further comprises isolating or enriching one or more of the four distinct maturation subsets of immunosuppressive regulatory T-cell populations.

26. The method of Claim 25, wherein the method further comprises contacting the one or more of the four distinct maturation subsets of immunosuppressive regulatory T-cell populations with a stimulatory composition thereby expanding population of immunosuppressive regulatory T-cells.

27. Use of an α-CD6 antibody in the manufacture of a medicament for enriching immunosuppressive regulatory T-cells in an individual, wherein the administration renders inoperable T-cells comprising a $CD6^{hi/+}$ expression pattern, but not T-cells comprising a $CD6^{low/-}$ expression pattern, thereby enriching for a population of immunosuppressive regulatory T-cells in the individual, and wherein the individual having an immune-based disorder, the immune-based disorder is selected from a group consisting of an autoimmune condition, autoimmune disorder, autoimmune disease, a transplant rejection, a graft vs. host disease, a cancer, immune-based inflammatory diseases, allergies, asthma, persistent and progressive immune reactions to infectious non self-antigens that persist within mammals and humans and combinations of the immune-based disorders, and wherein the antigen is selected from a group consisting of bacterial, viral, fungal, or parasitic organisms.